| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Moriya Tsuji | Q37842009 |
| P2860 | cites work | Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: involvement of interferon gamma and CD8+ T cells | Q24679783 |
| Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei | Q28259011 | ||
| Characterization of Plasmodium falciparum sporozoite surface protein 2 | Q30044857 | ||
| Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data | Q30814677 | ||
| Immunization with radiation-attenuated Plasmodium berghei sporozoites induces liver cCD8alpha+DC that activate CD8+T cells against liver-stage malaria | Q33426868 | ||
| Cytotoxic T-lymphocyte epitopes for HLA-B53 and other HLA types in the malaria vaccine candidate liver-stage antigen 3 | Q34003047 | ||
| Thrombospondin related anonymous protein (TRAP) of Plasmodium falciparum binds specifically to sulfated glycoconjugates and to HepG2 hepatoma cells suggesting a role for this molecule in sporozoite invasion of hepatocytes | Q34055744 | ||
| Short-term antigen presentation and single clonal burst limit the magnitude of the CD8(+) T cell responses to malaria liver stages. | Q34154441 | ||
| Nitric oxide-mediated antiplasmodial activity in human and murine hepatocytes induced by gamma interferon and the parasite itself: enhancement by exogenous tetrahydrobiopterin | Q34538328 | ||
| IFN-gamma inhibits development of Plasmodium berghei exoerythrocytic stages in hepatocytes by an L-arginine-dependent effector mechanism. | Q34888899 | ||
| Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection | Q34990090 | ||
| The in vivo cytotoxic activity of CD8+ T cell clones correlates with their levels of expression of adhesion molecules | Q36231136 | ||
| Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection | Q36343693 | ||
| Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes | Q36350636 | ||
| CD4+ cytolytic T cell clone confers protection against murine malaria | Q36353821 | ||
| Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity | Q36366362 | ||
| Genetically attenuated Plasmodium berghei liver stages induce sterile protracted protection that is mediated by major histocompatibility complex Class I-dependent interferon-gamma-producing CD8+ T cells | Q36674065 | ||
| Effector CD8+ T lymphocytes against liver stages of Plasmodium yoelii do not require gamma interferon for antiparasite activity | Q36804164 | ||
| Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria | Q36893651 | ||
| CD8 T cell immunity to Plasmodium permits generation of protective antibodies after repeated sporozoite challenge. | Q37382198 | ||
| CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites | Q37483705 | ||
| Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria. | Q39824887 | ||
| Plasmodium berghei-infected primary hepatocytes process and present the circumsporozoite protein to specific CD8+ T cells in vitro | Q40130323 | ||
| Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites | Q41386252 | ||
| Molecular analysis of the association of HLA-B53 and resistance to severe malaria | Q41590293 | ||
| Cytotoxic CD4+ T cells from a sporozoite-immunized volunteer recognize the Plasmodium falciparum CS protein | Q41663517 | ||
| Class II-restricted protective immunity induced by malaria sporozoites | Q41825623 | ||
| Characterization of the gene encoding sporozoite surface protein 2, a protective Plasmodium yoelii sporozoite antigen | Q42607482 | ||
| Generation and characterization of malaria-specific human CD8(+) lymphocyte clones: effect of natural polymorphism on T cell recognition and endogenous cognate antigen presentationby liver cells | Q43934779 | ||
| CD8+ T lymphocytes protective against malaria liver stages are primed in skin-draining lymph nodes. | Q44137388 | ||
| The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites | Q44170879 | ||
| Elimination of P. berghei liver stages is independent of Fas (CD95/Apo-I) or perforin-mediated cytotoxicity | Q44174926 | ||
| The complexity of protective immunity against liver-stage malaria | Q44444824 | ||
| Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria | Q44662956 | ||
| A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease | Q46950134 | ||
| Interferon-gamma-independent CD8+ T cell-mediated protective anti-malaria immunity elicited by recombinant adenovirus | Q47858747 | ||
| CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria | Q47863985 | ||
| Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein | Q47868152 | ||
| Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria | Q47888641 | ||
| IL-4-secreting CD4+ T cells are crucial to the development of CD8+ T-cell responses against malaria liver stages. | Q47898789 | ||
| Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon | Q47907672 | ||
| Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria | Q47910752 | ||
| Opsonization by antigen-specific antibodies as a mechanism of protective immunity induced by Plasmodium falciparum circumsporozoite protein-based vaccine | Q47928917 | ||
| Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite | Q47989675 | ||
| Development of antimalaria immunity in mice lacking IFN-gamma receptor. | Q47999419 | ||
| Effector functions of circumsporozoite peptide-primed CD4+ T cell clones against Plasmodium yoelii liver stages | Q48002443 | ||
| The relative contribution of antibodies, CD4+ and CD8+ T cells to sporozoite-induced protection against malaria | Q48008421 | ||
| Intrasplenic immunization with infected hepatocytes: a mouse model for studying protective immunity against malaria pre-erythrocytic stage. | Q48008854 | ||
| The role of CD4+ T cells in immunity to malaria sporozoites | Q48014185 | ||
| Human CD4+ T cells induced by synthetic peptide malaria vaccine are comparable to cells elicited by attenuated Plasmodium falciparum sporozoites | Q48019900 | ||
| MHC class I-dependent presentation of exoerythrocytic antigens to CD8+ T lymphocytes is required for protective immunity against Plasmodium berghei. | Q48026836 | ||
| Protection against malaria by Plasmodium yoelii sporozoite surface protein 2 linear peptide induction of CD4+ T cell- and IFN-gamma-dependent elimination of infected hepatocytes | Q48033332 | ||
| Plasmodium yoelii: peptide immunization induces protective CD4+ T cells against a previously unrecognized cryptic epitope of the circumsporozoite protein | Q48034036 | ||
| Swift development of protective effector functions in naive CD8(+) T cells against malaria liver stages | Q95721559 | ||
| P433 | issue | 3 | |
| P921 | main subject | malaria | Q12156 |
| malaria vaccine | Q6741353 | ||
| P304 | page(s) | 421-425 | |
| P577 | publication date | 2009-11-26 | |
| P1433 | published in | Experimental Parasitology | Q15754029 |
| P1476 | title | A retrospective evaluation of the role of T cells in the development of malaria vaccine | |
| P478 | volume | 126 |
| Q47581449 | A potent malaria vaccine based on adenovirus with dual modifications at Hexon and pVII. |
| Q40270575 | CD8+ T-cell mediated anti-malaria protection induced by malaria vaccines; assessment of hepatic CD8+ T cells by SCBC assay |
| Q34012311 | Circumsporozoite protein-specific K(d)-restricted CD8+ T cells mediate protective antimalaria immunity in sporozoite-immunized MHC-I-K(d) transgenic mice |
| Q38156198 | Clinical applications of attenuated MVA poxvirus strain. |
| Q37824065 | Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant |
| Q34399831 | Cytotoxic markers associate with protection against malaria in human volunteers immunized with Plasmodium falciparum sporozoites |
| Q26750593 | Dendritic Cells and Their Multiple Roles during Malaria Infection |
| Q38872073 | Development of whole sporozoite malaria vaccines |
| Q37371348 | Experimental models in vaccine research: malaria and leishmaniasis |
| Q30561036 | Imaging Plasmodium immunobiology in the liver, brain, and lung |
| Q38794791 | Immune responses against protozoan parasites: a focus on the emerging role of Nod-like receptors |
| Q31103100 | Immunity to malaria in Plasmodium vivax infection: a study in central China |
| Q38103059 | Immunobiology of Plasmodium in liver and brain |
| Q27310073 | In vivo CD8+ T cell dynamics in the liver of Plasmodium yoelii immunized and infected mice |
| Q41938035 | Interferon-γ, a valuable surrogate marker of Plasmodium falciparum pre-erythrocytic stages protective immunity |
| Q36510147 | Large screen approaches to identify novel malaria vaccine candidates |
| Q33868760 | New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model |
| Q41693606 | Profiling the Targets of Protective CD8+ T Cell Responses to Infection |
| Q35051549 | Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites |
| Q34999392 | The case for a rational genome-based vaccine against malaria. |
Search more.